Efficacy and Safety of Clopidogrel in the Prevention of Primary Failure of Arteriovenous Fistula in Patients with End-Stage Renal Disease

Abstract

Introduction

Primary failure of arteriovenous fistulas (AVFs) is a significant complication for patients with end-stage renal disease (ESRD) requiring hemodialysis , with failure rates reported to be as high as 20% to 54%. Thrombosis is a primary cause, accounting for the majority of these failures. This review synthesizes evidence from key studies to evaluate the efficacy and safety of clopidogrel as a prophylactic intervention to improve AVF patency and maturation.

Methods

This abstract is based on a critical review of literature, including randomized controlled trials (RCTs) and systematic reviews, examining the role of antiplatelet therapy in AVF outcomes. The primary intervention analyzed was the administration of 75 mg of clopidogrel daily, initiated prior to AVF creation. Studies also assessed combination therapies, such as clopidogrel with an oral prostacycline analog. The main outcome measured across the literature was the rate of primary AVF failure and successful long-term patency.

Results

The evidence consistently indicates that prophylactic administration of clopidogrel significantly reduces the incidence of primary AVF failure compared to placebo. An RCT by Ghorbani et al. demonstrated that starting clopidogrel 7–10 days before surgery effectively mitigated vascular failure with manageable side effects. Furthermore, a study by Abacilar et al. found that combining clopidogrel with a prostacycline analog promoted both early maturation and long-term AVF survival. A systematic review by Siddiqui et al. reinforced the positive influence of antiplatelet agents on patency rates.

Discussion

The therapeutic benefit of clopidogrel is primarily attributed to its antiplatelet properties, which counteract the thrombotic events responsible for most early AVF failures. By inhibiting platelet activation and aggregation at the site of endothelial injury, clopidogrel helps maintain fistula patency during the critical maturation period. The findings suggest that pharmacological intervention is a key component of a multifaceted approach to optimizing vascular access health, addressing underlying issues like endothelial dysfunction and inflammation.

Conclusion

The collective evidence strongly supports the efficacy and safety of clopidogrel in the prevention of primary AVF failure among ESRD patients. The inclusion of antiplatelet therapy, specifically clopidogrel, should be considered a vital component in the standard management of vascular access for hemodialysis to improve patient outcomes.